AIMS: Heme derived from hemolysis is pro-oxidative and proinflammatory and promotes vaso-occlusion in murine models of sickle cell disease (SCD), suggesting that enhanced detoxification of heme may be beneficial. Nuclear factor erythroid-2-related factor-2 (Nrf2) transcription pathway is the principal cellular defense system responding to pro-oxidative and proinflammatory stress. Dimethyl fumarate (DMF), a drug approved for treatment of multiple sclerosis, provides neuroprotection by activating Nrf2-responsive genes. We hypothesized that induction of Nrf2 with DMF would be beneficial in murine SCD models. RESULTS: DMF (30 mg/kg/day) or vehicle (0.08% methyl cellulose) was administered for 3-7 days to NY1DD and HbSS-Townes SCD mice. Vaso-occlusion, a hallmark of SCD, measured in sickle mice with dorsal skinfold chambers, was inhibited by DMF. The inhibitory effect of DMF was abrogated by the heme oxygenase-1 (HO-1) inhibitor tin protoporphyrin. DMF increased nuclear Nrf2 and cellular mRNA of Nrf2-responsive genes in livers and kidneys. DMF increased heme defenses, including HO-1, haptoglobin, hemopexin, and ferritin heavy chain, although plasma hemoglobin and heme levels were unchanged. DMF decreased markers of inflammation, including nuclear factor-kappa B phospho-p65, adhesion molecules, and toll-like receptor 4. DMF administered for 24 weeks to HbSS-Townes mice decreased hepatic necrosis, inflammatory cytokines, and irregularly shaped erythrocytes and increased hemoglobin F, but did not alter hematocrits, reticulocyte counts, lactate dehydrogenase, plasma heme, or spleen weights, indicating that the beneficial effects of DMF were not attributable to decreased hemolysis. INNOVATION: These studies identify Nrf2 activation as a new therapeutic target for the treatment of SCD. CONCLUSION: DMF activates Nrf2, enhances antioxidant defenses, and inhibits inflammation and vaso-occlusion in SCD mice. Antioxid. Redox Signal. 26, 748-762.
AIMS: Heme derived from hemolysis is pro-oxidative and proinflammatory and promotes vaso-occlusion in murine models of sickle cell disease (SCD), suggesting that enhanced detoxification of heme may be beneficial. Nuclear factor erythroid-2-related factor-2 (Nrf2) transcription pathway is the principal cellular defense system responding to pro-oxidative and proinflammatory stress. Dimethyl fumarate (DMF), a drug approved for treatment of multiple sclerosis, provides neuroprotection by activating Nrf2-responsive genes. We hypothesized that induction of Nrf2 with DMF would be beneficial in murineSCD models. RESULTS:DMF (30 mg/kg/day) or vehicle (0.08% methyl cellulose) was administered for 3-7 days to NY1DD and HbSS-Townes SCDmice. Vaso-occlusion, a hallmark of SCD, measured in sickle mice with dorsal skinfold chambers, was inhibited by DMF. The inhibitory effect of DMF was abrogated by the heme oxygenase-1 (HO-1) inhibitor tin protoporphyrin. DMF increased nuclear Nrf2 and cellular mRNA of Nrf2-responsive genes in livers and kidneys. DMF increased heme defenses, including HO-1, haptoglobin, hemopexin, and ferritin heavy chain, although plasma hemoglobin and heme levels were unchanged. DMF decreased markers of inflammation, including nuclear factor-kappa B phospho-p65, adhesion molecules, and toll-like receptor 4. DMF administered for 24 weeks to HbSS-Townes micedecreased hepatic necrosis, inflammatory cytokines, and irregularly shaped erythrocytes and increased hemoglobin F, but did not alter hematocrits, reticulocyte counts, lactate dehydrogenase, plasma heme, or spleen weights, indicating that the beneficial effects of DMF were not attributable to decreased hemolysis. INNOVATION: These studies identify Nrf2 activation as a new therapeutic target for the treatment of SCD. CONCLUSION:DMF activates Nrf2, enhances antioxidant defenses, and inhibits inflammation and vaso-occlusion in SCDmice. Antioxid. Redox Signal. 26, 748-762.
Authors: Christopher J Bean; Sheree L Boulet; Dorothy Ellingsen; Meredith E Pyle; Emily A Barron-Casella; James F Casella; Amanda B Payne; Jennifer Driggers; Heidi A Trau; Genyan Yang; Kimberly Jones; Solomon F Ofori-Acquah; W Craig Hooper; Michael R DeBaun Journal: Blood Date: 2012-09-10 Impact factor: 22.113
Authors: Brian N Chorley; Michelle R Campbell; Xuting Wang; Mehmet Karaca; Deepa Sambandan; Fatu Bangura; Peng Xue; Jingbo Pi; Steven R Kleeberger; Douglas A Bell Journal: Nucleic Acids Res Date: 2012-05-11 Impact factor: 16.971
Authors: Alessandro Matte; Antonio Recchiuti; Enrica Federti; Bérengère Koehl; Thomas Mintz; Wassim El Nemer; Pierre-Louis Tharaux; Valentine Brousse; Immacolata Andolfo; Alessia Lamolinara; Olga Weinberg; Angela Siciliano; Paul C Norris; Ian R Riley; Achille Iolascon; Charles N Serhan; Carlo Brugnara; Lucia De Franceschi Journal: Blood Date: 2018-11-07 Impact factor: 22.113
Authors: Viktoria Kuhn; Lukas Diederich; T C Stevenson Keller; Christian M Kramer; Wiebke Lückstädt; Christina Panknin; Tatsiana Suvorava; Brant E Isakson; Malte Kelm; Miriam M Cortese-Krott Journal: Antioxid Redox Signal Date: 2017-01-18 Impact factor: 8.401
Authors: Sriram Krishnamoorthy; Betty Pace; Dipti Gupta; Sarah Sturtevant; Biaoru Li; Levi Makala; Julia Brittain; Nancy Moore; Benjamin F Vieira; Timothy Thullen; Ivan Stone; Huo Li; William E Hobbs; David R Light Journal: JCI Insight Date: 2017-10-19
Authors: Gregory M Vercellotti; Ping Zhang; Julia Nguyen; Fuad Abdulla; Chunsheng Chen; Phong Nguyen; Carlos Nowotny; Clifford J Steer; Ann Smith; John D Belcher Journal: Mol Med Date: 2016-07-19 Impact factor: 6.354